Generex Biotechnology Makes Poster Presentations of Clinical Data at International Diabetes Federation 19th World Diabetes Congress
Tuesday December 5, 7:00 am ET
TORONTO--(MARKET WIRE)--Dec 5, 2006 -- Generex Biotechnology Corporation (NASDAQ:GNBT - News), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that it made two poster presentations of clinical data at the International Diabetes Federation 19th World Diabetes Congress (www.idf2006.org) in Cape Town, South Africa, December 3 - 7, 2006.
ADVERTISEMENT
The first poster, entitled "Metformin Gum: An Alternative Method for Delivery of Biguanides," was authored by Drs. Jaime Guevara-Aguirre, David Saldarreaga, Marco Guevara-Aguirre, and Jeannette Saavedra of the Institute of Endocrinology IEMYR in Quito, Ecuador, and Dr. Gerald Bernstein, the Company's Vice-President - Medical Affairs.
The second poster, entitled "3-Month Interim Results (6-Month Study) on Safety and Efficacy of an Oral Insulin (Generex Oral-lyn(TM)) Administered at Lunchtime in Juvenile Type-1 Diabetes Mellitus Subjects Maintained on Basal Glargine Insulin and Pre-Breakfast and Pre-Dinner Regular Insulin," was authored by Drs. Jaime Guevara-Aguirre, Marco Guevara-Aguirre and Jeannette Saavedra, all of the Institute of Endocrinology IEMYR in Quito, Ecuador.
The World Diabetes Congress attracts the highest level of international expertise in diabetes, provides a platform for discussion of the latest scientific advances in the field, and offers practical information on diabetes care, advocacy and awareness.
The International Diabetes Federation (IDF) is the global advocate for the more than 200 million people with diabetes worldwide. It represents 197 Diabetes Associations in 157 countries. The mission of IDF is to promote diabetes care, prevention and a cure worldwide. IDF is a non-governmental organization in official relations with the World Health Organization (WHO). |
